Vivanza Biosciences Intrinsic Value
Vivanza Biosciences intrinsic value. Vivanza Biosciences (VIVANZA) median intrinsic value is ₹2.88 from 7 valuation models (range ₹1–₹4), vs current price ₹1.44 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Analyse VIVANZA shareholder distribution to track promoter, FII and institutional holdings.
VIVANZA Valuation Methods Summary — DCF, Graham Number & P/E
Vivanza Biosciences intrinsic value across 7 models vs current price ₹1.44 — upside/downside and value range per method. Browse VIVANZA annual financials for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2.64 | ₹2.11 - ₹3.17 | +83.3% | EPS: ₹0.12, Sector P/E: 22x |
| Book Value Method | asset | ₹3.60 | ₹3.24 - ₹3.96 | +150.0% | Book Value/Share: ₹10.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2.88 | ₹2.59 - ₹3.17 | +100.0% | Revenue/Share: ₹110.00, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹3.60 | ₹2.88 - ₹4.32 | +150.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹0.77 | ₹0.69 - ₹0.85 | -46.5% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1.85 | ₹1.67 - ₹2.04 | +28.5% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹4.32 | ₹3.89 - ₹4.75 | +200.0% | EPS: ₹0.12, BVPS: ₹10.00 |
VIVANZA Intrinsic Value vs Market Price — All Valuation Models
Vivanza Biosciences fair value range ₹1–₹4 vs current market price ₹1.44 across 7 valuation models. For current market price and key ratios, visit Vivanza Biosciences stock price NSE.
VIVANZA Intrinsic Value Analysis — Undervalued or Overvalued?
Vivanza Biosciences median intrinsic value ₹2.88, current price ₹1.44 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of VIVANZA?
Based on our comprehensive analysis using 7 different valuation methods, the estimated intrinsic value of Vivanza Biosciences (VIVANZA) is ₹2.88 (median value). With the current market price of ₹1.44, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹0.77 to ₹4.32, indicating ₹0.77 - ₹4.32.
Is VIVANZA undervalued or overvalued?
Based on our multi-method analysis, Vivanza Biosciences (VIVANZA) appears to be trading below calculated value by approximately 100.0%.
VIVANZA Financial Health — Key Ratios vs Industry Benchmarks
Vivanza Biosciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Operating Margin | 2.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 2.00x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
VIVANZA Cash Flow Quality — Operating & Free Cash Flow
Vivanza Biosciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |